CSPC Pharmaceutical Group is a leading pharmaceutical group in China and is listed on the Hong Kong Stock Exchange. The company focuses on finished and bulk drugs with innovative medicines as its core development strategy.
CSPC Pharmaceutical Group has received approval from China's National Medical Products Administration to begin clinical trials for three drug candidates: a hemophilia A biosimilar, a long-acting pain medication, and an injection designated SYH9089.
Global pharmaceutical companies are accelerating licensing deals for China-developed experimental medicines, with deal values reaching unprecedented levels in 2026 as firms cut costs ahead of patent expirations.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06224842 |
Clinical Study of Mitoxantrone Liposome and Azacitidine in the Treatment of R/R AITL |
RECRUITING | PHASE1/PHASE2 |
